An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Jianqing Lin, Aileen Deng, Jean Hoffman-Censits, Geoffrey Gibney, Terry Hyslop, Brooke Miller, Deborah Kilpatrick, Serge Jabbour, William Kevin Kelly

Research output: Contribution to journalArticlepeer-review

Abstract

New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.

Original languageEnglish (US)
Pages (from-to)192-195
Number of pages4
JournalCancer Treatment Communications
Volume4
DOIs
StatePublished - 2015
Externally publishedYes

Keywords

  • Castrate-resistant
  • Everolimus
  • Pasireotide
  • Phase II
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients'. Together they form a unique fingerprint.

Cite this